

Initial Prior Authorization with Quantity Limit Nereus

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Nereus	tradipitant

Indications

FDA-approved Indications

Nereus is indicated for the prevention of vomiting induced by motion in adults.

Coverage Criteria

Prevention of Vomiting

Authorization may be granted when the requested drug is being prescribed for the prevention of vomiting induced by motion in an adult when ALL of the following criteria are met:

- The patient meets ONE of the following:
 - The patient has experienced an inadequate treatment response to a first-generation antihistamine (e.g., dimenhydrinate, meclizine) AND transdermal scopolamine.

Reference number(s)
7473-C

- The patient has experienced an intolerance to a first-generation antihistamine (e.g., dimenhydrinate, meclizine) AND transdermal scopolamine.
- The patient has a contraindication that would prohibit a trial of a first-generation antihistamine (e.g., dimenhydrinate, meclizine) AND transdermal scopolamine.
- If additional quantities are being requested, then the patient is taking a 170 mg dose or the duration of the event expected to cause vomiting induced by motion exceeds the limit.

Quantity Limits Apply

8 capsules per 25 days

170 mg dose or duration of event exceeds limit: 16 capsules per 25 days

This drug is for short-term acute use; therefore, the intent is for prescriptions of the requested drug to be filled one month at a time; there should be no 3 month supplies filled.

Duration of Approval (DOA)

- 7473-C: DOA: 1 month

References

1. Nereus [package insert]. Washington, DC: Vanda Pharmaceuticals Inc.; March 2026.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2026. <https://online.lexi.com>. Accessed April 21, 2026.
3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 04/20/2026).
4. Brainard A, Gresham C. Prevention and treatment of motion sickness. American Family Physician. 2014;90(1):41-46.